Slide 1: BioLargo: We Make Life Better
S BioLargo We Make Life Better Better Solutions for: Air - Water - Energy Strategy: Stock Symbol: isn Invent, Prove, Partner BLGO
Slide 2: Safe Harbor Statement
Safe Harbor Statement All statements, other than stater and management’ ex id similar expressions, looking statem in these identi timated or expected the forward-looking events and citcumstanc aceul, and actual results could differ mat i statements, Any fo srrently available t
Slide 3: Who we are
Who we are > Innovators, > Passionate about > Driven by a scientists, sustainability and mission to make engineers, and human health life better entrepreneurs
Slide 4: What we do
What we do > Best-in-class > Engineering- > Focus on solutions for forward problems without cleantech problems technologies solutions
Slide 5: Operating Segments
Operating Segments Commercializing our Technologies Innovation Engine TECHNOLOGIES (y BioLargo BioLargo We Make Life Better The BioLargo e CWWRA ENERGY \G}BioLargo — Engineering ( Biarge —
Slide 6: Revenue (Past Years)
$ MILLIONS $140 $12.0 $10.0 REVENUE (PAST 6 YEARS) 2018 2019 «2020 = 2021 2022 = 2023 Trends are not necessarily indicative of future performance (Biobarge 6
Slide 7: Quarterly Revenue and SG&A
MILLIONS QUARTERLY REVENUE AND SG&A 2022 Key highlights from Q1 2024: Revenue + Qi was $4,760,000, an increase of $390,000 over Qa4’s $4,370,000 + 9% quarter-over-quarter increase + 28% increase compared to Qt 2023 Cash generated from operating activities: * QI cash flow of $481,000, an increase of
Slide 8: 2024 Revenue Run Rate Scenarios
$ MILLIONS 2024 REVENUE RUN RATE SCENARIOS s 2018 «2019 2020 2021 2022 2023 2024 Current revenue run rate Q1 2024 revenue was $4,760,000 Trends are not necessarily indicative of future performance, and future revenues are highly dependent on our partners’ performance.
Slide 9: Net Stockholder's Equity
MILLIONS NET STOCKHOLDER'S EQUITY 2018 2008 so) $2) Trends are not necessarily indicative of future performance $0) 2021 2022 2023 1 OF 2024
Slide 10: POOPH - Consumer pet odor product
POOPH - Consumer pet odor product Product marketed and sold by our partners, award-winning consumer product experts (Ikigai Marketing Works) ONM receives manufacturer's margin and a royalty on sales. Business strategy: ramp up sales and sell to a major consumer products company + ONM would receive 2
Slide 11: Pooph - Looking Forward
Pooph - Looking Forward Current status: Revenues continuing to grow as predicted Retail presence continues to expand Pooph continues to sell via direct-to-consumer, Walmart, Amazon, Ace Hardware, Home Depot, and others 30K+ stores already New products for 2024: wipes launched, and puppy pads coming
Slide 12: Clyra Medical Technologies
@cwee Clyra Medical Technologies: THE CLYRADVANTAGE Clyra™ Antimicrobial Platform Infection Prevention & Control Supporting 3'-party FDA-compliant manufacturing with $800,000 of specialized equipment to support upcoming distribution (Bite | ia
Slide 13: PFAS: the Forever Chemicals Plaguing Water Supplies
PFAS: the “Forever Chemicals” Plaguing Water Supplies Around the World Thousands of sites — in wate } pubic
Slide 14: Standards for PFAS
ards for PFAS April 10 - EPA Finalized nking Water St Biden-Harris Administration Finalizes First- ¢ Ever National Drinking Water Standard to Pare Protect 100M People from PFAS Pollution t Ay ie Ir As part of the Administration’s commitment to combating PEAS pollution, EPA Millio announces $1B inves
Slide 15: Two PFAS Designated as Hazardous Substances
April 19 -Two PFAS Designated as Hazardous Substances Biden-Harris Administration Finalizes Critical Rule to Clean up PFAS Contamination to Protect $ Also an Public Health 708 in hpouna EPA action de es two widely used PFAS as hazardous substances under the FAS tre, dling f Superfund law, improving
Slide 16: Other regulatory drivers for PFAS
Other regulatory drivers for PFAS HAZARDOUS WASTE eb 8 notice of rulemaking for RCRA Appendix Vill for nine PFAS chemicals handled an even handling aste
Slide 17: AEC Aqueous Electrostatic Carbon Filtration
AEC AQUEOUS ELECTROSTATIC CARBON FILTRATION/ MEDIA FILTRATION 4 ( Biokargo GSiLarce
Slide 18: The PFAS treatment waste conundrum
The PFAS treatment waste conundrum What they don’t tell you about other PFAS capture technologies GAC-based |", filtration AEC produces less waste Disposal of PFAS-laden waste is expensive, difficult, and has regulatory implications
Slide 19: New Jersey PFAS treatment project
New Jersey PFAS treatment project t is underwa) See press release dated December 20, 2023: (Biota 19
Slide 20: Cellinity
\OO} C=LLINITY GBictaee | 20
Slide 21: Trends driving energy storage demand
Trends driving energy storage demand The potential impact of electric vehicles on global energy systems Takeaway: Takeaway: Al uses a lot more energy than most EVs a driving force for ‘electrification’, which is people realize, accelerating the unbalancing the grid and necessitating battery worlds e
Slide 22: The problems with lithium
The problems with lithium > Explosive > High risk of thermal runaway > Global supply chain risk > Poor environmental outcomes
Slide 23: Cellinity long duration energy storage
eg Cid RGY TECHNOLOGIES Better, safer, less expensive option for long duration energy storage (LDES) Non-venting, sealed design Longer lasting Performance does not degrade over thousands of charge/discharge cycles *a subsidiary of 100% domestic supply possible BioLargo, Inc.
Slide 24: How to monetize a new battery technology?
How to monetize a new battery technology? Choices: 3) Participate in energy production and delivery (power purchase agreements) Traditional thinking Generate cash flow early Risky, expensive g + A future opportunity once J battery manufacture and Requires too much capital, too much time supply chain
Slide 25: Commercialization Pathway
Commercialization Pathway 11 Biologe a @ EN=RGY Target market is worth billions TECHNOLOGIES Scale up Build ; cells and component Complete pilot battery manufacturing manufacturing packs facility Make and Make Engage with test cells licensing partners as partnerships consulting engineer and licensin
Slide 26: The BioLargo Family of Companies
The BioLargo r(S BioLargo Family of Companies OTCQB: BLGO Dennis Calvert +] CLYRA Bigharae